Literature DB >> 25713732

Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?

Colleen M Hanley1, Peter R Kowey1.   

Abstract

Atrial fibrillation (AF) is associated with significant morbidity and mortality related to stroke due to thromboembolism. Several novel oral anticoagulants (NOACs) have been developed that dose-dependently inhibit thrombin or activated factor X (factor Xa). These new agents offer potential advantages over vitamin K antagonists, however, several limitations exist. We will review the four large randomized trials comparing the efficacy and safety of new oral anticoagulants with warfarin for stroke prevention in patients with AF as well as assess "real world" data and discuss the limitations of the new agents.

Entities:  

Keywords:  Anticoagulants; atrial fibrillation (AF); hemorrhage; stroke; warfarin

Year:  2015        PMID： 25713732      PMCID： PMC4321074          DOI： 10.3978/j.issn.2072-1439.2015.01.23

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


  28 in total

1.  Newly identified events in the RE-LY trial.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; Paul A Reilly; Lars Wallentin
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

2.  Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Authors:  James V Freeman; Ruo P Zhu; Douglas K Owens; Alan M Garber; David W Hutton; Alan S Go; Paul J Wang; Mintu P Turakhia
Journal:  Ann Intern Med       Date:  2010-11-01       Impact factor: 25.391

3.  Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.

Authors:  John W Eikelboom; Lars Wallentin; Stuart J Connolly; Mike Ezekowitz; Jeff S Healey; Jonas Oldgren; Sean Yang; Marco Alings; Scott Kaatz; Stefan H Hohnloser; Hans-Christoph Diener; Maria Grazia Franzosi; Kurt Huber; Paul Reilly; Jeanne Varrone; Salim Yusuf
Journal:  Circulation       Date:  2011-05-16       Impact factor: 29.690

4.  Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on Pradaxa (dabigatran).

Authors:  Eeric Truumees; Tracy Gaudu; Chad Dieterichs; Matthew Geck; John Stokes
Journal:  Spine (Phila Pa 1976)       Date:  2012-06-15       Impact factor: 3.468

5.  Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment.

Authors:  Maura K Wychowski; Peter A Kouides
Journal:  Ann Pharmacother       Date:  2012-04-10       Impact factor: 3.154

6.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

Review 7.  Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data.

Authors:  Michael Hughes; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2008-02       Impact factor: 5.249

8.  Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.

Authors:  Jonathan P Piccini; Susanna R Stevens; YuChiao Chang; Daniel E Singer; Yuliya Lokhnygina; Alan S Go; Manesh R Patel; Kenneth W Mahaffey; Jonathan L Halperin; Günter Breithardt; Graeme J Hankey; Werner Hacke; Richard C Becker; Christopher C Nessel; Keith A A Fox; Robert M Califf
Journal:  Circulation       Date:  2012-12-03       Impact factor: 29.690

9.  Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.

Authors:  Alan S Go; Margaret C Fang; Natalia Udaltsova; Yuchiao Chang; Niela K Pomernacki; Leila Borowsky; Daniel E Singer
Journal:  Circulation       Date:  2009-03-02       Impact factor: 29.690

10.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245
View more
  16 in total

1. 

Authors:  Nicholas R Jones; F D Richard Hobbs; Clare J Taylor
Journal:  Can Fam Physician       Date:  2017-12       Impact factor: 3.275

2.  Underuse of anticoagulation therapy for atrial fibrillation: Are we failing our patients?

Authors:  Nicholas R Jones; F D Richard Hobbs; Clare J Taylor
Journal:  Can Fam Physician       Date:  2017-12       Impact factor: 3.275

Review 3.  Addressing Multimorbidity and Polypharmacy in Individuals With Atrial Fibrillation.

Authors:  Fahad Shaikh; Lachlan B Pasch; Phillip J Newton; Beata V Bajorek; Caleb Ferguson
Journal:  Curr Cardiol Rep       Date:  2018-03-24       Impact factor: 2.931

4.  Apixaban-Induced Resolution of A Massive Left Atrial and Appendage Thrombosis in a Very Elderly Patient.

Authors:  Gloria Santangelo; Alfonso Ielasi; Pasquale Antonio Scopelliti; Francesco Pattarino; Maurizio Tespili
Journal:  J Atr Fibrillation       Date:  2016-12-31

5.  PURLs: The benefits--and limits--of PPIs with warfarin regimens.

Authors:  Alicia Ludden-Schlatter; James J Stevermer
Journal:  J Fam Pract       Date:  2017-11       Impact factor: 0.493

6.  Is there consensus on the perioperative management of Xa inhibitors in patients undergoing elective spine surgery?-A survey of current spine surgeon practices.

Authors:  Ashley E Xiong; Taylor J Jackson; Bryan Kinsey Lawson; Navid Khezri; Arjun Sebastian; Brett Freedman; Benjamin Elder; Bradford Currier
Journal:  J Spine Surg       Date:  2021-12

7.  Acute haemorrhage rate in 28,000 Out-of-Hours CT heads.

Authors:  Katherine C Hocking; Catriona R Wright; Utku Alhun; Frances Hughes; Vartan J Balian; Mohammed A K Kabuli; George Tse; Maria McGonnell; Annu Chopra; Nikhil Kotnis; Daniel Connelly; Samer Alabed
Journal:  Br J Radiol       Date:  2022-01-05       Impact factor: 3.039

8.  The Safety and Efficacy of Apixaban (Eliquis) in 5017 Post-bariatric Patients with 95.3% Follow-up: a Multicenter Study.

Authors:  Amit Surve; James Potts; Daniel Cottam; Mitchell Roslin; Walter Medlin; Miro Uchal; Christina Richards; Legrand Belnap
Journal:  Obes Surg       Date:  2022-04-27       Impact factor: 3.479

9.  Can a Short Video Improve Apixaban Knowledge in an Inpatient Setting?

Authors:  Christopher Giuliano; Thomas Nofar; Stephanie B Edwin
Journal:  P T       Date:  2017-04

10.  Low rates of liver injury in edoxaban users: Evidence from a territory-wide observational cohort study.

Authors:  Jiandong Zhou; Keith Sai Kit Leung; Dicken Kong; Sharen Lee; Tong Liu; Abraham Ka Chung Wai; Carlin Chang; Qingpeng Zhang; Gary Tse
Journal:  Clin Cardiol       Date:  2021-02-16       Impact factor: 2.882
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.